PMID- 35708757
OWN - NLM
STAT- MEDLINE
DCOM- 20220805
LR  - 20220816
IS  - 1437-160X (Electronic)
IS  - 0172-8172 (Linking)
VI  - 42
IP  - 9
DP  - 2022 Sep
TI  - Assessment of serum and synovial fluid MMP-3 and MPO as biomarkers for psoriatic 
      arthritis and their relation to disease activity indices.
PG  - 1605-1615
LID - 10.1007/s00296-022-05159-4 [doi]
AB  - Research on biomarkers for the diagnosis and monitoring of psoriatic arthritis 
      (PsA) is ongoing. The purpose of this study was to assess the potential of serum 
      and synovial fluid matrix metalloproteinase-3 (MMP-3) and myeloperoxidase (MPO) 
      as biomarkers for PsA and their relation to disease activity indices. This 
      case-control study involved 156 psoriatic arthritis patients, 50 gonarthrosis 
      patients, and 30 healthy controls. The target parameters were measured with the 
      enzyme-linked immunosorbent assay (ELISA) kits. Serum MMP-3 and MPO levels were 
      elevated in the PsA patients in comparison to the two control groups (p < 0.001) 
      and distinguished PsA from GoA patients and healthy controls with 100% accuracy. 
      Synovial MMP-3 discriminated PsA from GoA patients irrespective of the presence 
      of crystals (AUC = 1.00). PsA patients with crystals in the synovial fluid had 
      elevated synovial MPO (p < 0.001) and were distinguished from PsA patients 
      without crystals with accuracy of 88.50% and from GoA patients with accuracy of 
      88.30%. Synovial fluid MPO was positively associated with the following 
      indicators of disease activity: VAS (r(s) = 0.396); DAPSA (r(s) = 0.365); mCPDAI 
      (r(s) = 0.323). Synovial MMP-3 showed a weaker positive association with DAPSA 
      (r(s) = 0.202) and mCPDAI (r(s) = 0.223). Our results suggest that serum MMP-3 
      and MPO could serve as biomarkers for PsA. Synovial fluid MMP-3 showed a 
      potential as a biomarker for PsA versus GoA. Synovial MPO could be utilized as a 
      marker for the presence of crystals in PsA patients.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Geneva-Popova, Mariela
AU  - Geneva-Popova M
AUID- ORCID: 0000-0002-7655-3846
AD  - Department of Propedeutic of Internal Diseases, Clinic of Rheumatology, Medical 
      University of Plovdiv, University General Hospital "SvetiGeorgi", Plovdiv, 
      Bulgaria. genevapopova@yahoo.com.
FAU - Popova-Belova, Stanislava
AU  - Popova-Belova S
AUID- ORCID: 0000-0002-5808-6586
AD  - Department of Propedeutic of Internal Diseases, Clinic of Rheumatology, Medical 
      University of Plovdiv, University General Hospital "SvetiGeorgi", Plovdiv, 
      Bulgaria.
FAU - Popova, Velichka
AU  - Popova V
AUID- ORCID: 0000-0001-5733-5520
AD  - Clinic of Rheumatology, Medical University of Plovdiv, University General 
      Hospital "Kaspela", Plovdiv, Bulgaria.
FAU - Chompalov, Kostadin
AU  - Chompalov K
AUID- ORCID: 0000-0002-4636-1384
AD  - Department of Rheumatology, Medical University, University General Hospital "St. 
      Georgi", Plovdiv, Bulgaria.
FAU - Batalov, Anastas
AU  - Batalov A
AUID- ORCID: 0000-0001-8857-0574
AD  - Department of Propedeutic of Internal Diseases, Clinic of Rheumatology, Medical 
      University of Plovdiv, University General Hospital "Kaspela", Plovdiv, Bulgaria.
LA  - eng
PT  - Journal Article
DEP - 20220616
PL  - Germany
TA  - Rheumatol Int
JT  - Rheumatology international
JID - 8206885
RN  - 0 (Biomarkers)
RN  - EC 1.11.1.7 (MPO protein, human)
RN  - EC 1.11.1.7 (Peroxidase)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - *Arthritis, Psoriatic/diagnosis
MH  - Biomarkers
MH  - Case-Control Studies
MH  - Humans
MH  - *Matrix Metalloproteinase 3/analysis/blood
MH  - *Peroxidase/analysis/blood
MH  - Synovial Fluid/chemistry
OTO - NOTNLM
OT  - Biomarkers
OT  - Matrix metalloproteinase 3
OT  - Myeloperoxidase
OT  - Psoriatic artritis
OT  - Synovial fluid
EDAT- 2022/06/17 06:00
MHDA- 2022/08/06 06:00
CRDT- 2022/06/16 11:53
PHST- 2022/04/10 00:00 [received]
PHST- 2022/05/25 00:00 [accepted]
PHST- 2022/06/17 06:00 [pubmed]
PHST- 2022/08/06 06:00 [medline]
PHST- 2022/06/16 11:53 [entrez]
AID - 10.1007/s00296-022-05159-4 [pii]
AID - 10.1007/s00296-022-05159-4 [doi]
PST - ppublish
SO  - Rheumatol Int. 2022 Sep;42(9):1605-1615. doi: 10.1007/s00296-022-05159-4. Epub 
      2022 Jun 16.